Home › Funds › Irenic Capital Management LP › TBPH

Irenic Capital Management LP position in TBPH

THERAVANCE BIOPHARMA INC

Irenic Capital Management LP reported holding 2,760,948 shares of TBPH (THERAVANCE BIOPHARMA INC) in its Q2 2026 13F filing — a position valued at US$46.9M, representing 2.48% of its reported portfolio and ranking #10 among its reported holdings. Irenic Capital Management LP has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.76M sh
Reported value held$46.94M
Portfolio Weight2.48%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Irenic Capital Management LP's TBPH position evolved

Irenic Capital Management LP first disclosed a stake in TBPH in Q3 2023 at 2,760,948 shares (US$23.8M). The position peaked in Q4 2025 at 2,760,948 shares, worth US$51.7M. Across 12 filings, Irenic Capital Management LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,760,948 shares valued at US$46.9M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.76M $23.83M New
Q4 2023 2.76M $31.03M Hold
Q1 2024 2.76M $24.77M Hold
Q2 2024 2.76M $23.41M Hold
Q3 2024 2.76M $22.25M Hold
Q4 2024 2.76M $25.98M Hold
Q1 2025 2.76M $24.66M Hold
Q2 2025 2.76M $30.45M Hold
Q3 2025 2.76M $40.31M Hold
Q4 2025 2.76M $51.66M Hold
Q1 2026 2.76M $44.81M Hold
Q2 2026 2.76M $46.94M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TBPH and 13F data

TBPH (THERAVANCE BIOPHARMA INC) is a company whose sector is not yet classified in our data. 31 other funds we track also report a position in TBPH — the largest reported positions include Madison Avenue Partners, LP (US$156.6M), Weiss Asset Management LP (US$126.8M), Newtyn Management, LLC (US$58.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TBPH

All TBPH fund holders →

FAQ

How long has Irenic Capital Management LP held TBPH?

Irenic Capital Management LP has disclosed TBPH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Irenic Capital Management LP's current position in TBPH?

As of Q2 2026, Irenic Capital Management LP holds 2.76M shares of TBPH (THERAVANCE BIOPHARMA INC), valued at $46.94M, representing 2.48% of its reported portfolio and ranking #10.

Has Irenic Capital Management LP been buying or selling TBPH?

In the latest 13F filing (Q2 2026), Irenic Capital Management LP held unchanged its position in TBPH. The position peaked in Q4 2025 at 2.76M shares.

Which other funds hold TBPH?

Other major institutional holders of TBPH include Madison Avenue Partners, LP, Weiss Asset Management LP, Newtyn Management, LLC, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.